News Releases

May 26, 2020 5/26/2020 Racing Against Time, Medical Researchers, Life Science Companies and COVID-19 Survivors Launch National Campaign to Drive Blood Plasma Donation

May 22, 2020 5/22/2020 U.S. FDA Approves Takeda’s ALUNBRIG® (brigatinib) as a First-Line Treatment Option for Patients Diagnosed with Rare and Serious Form of Lung Cancer

May 15, 2020 5/15/2020 Continuation of the Stock Compensation Plan for Directors and the Stock Grant System for Company Group Management in Fiscal Year 2020

May 15, 2020 5/15/2020 Notice of the Opinion of the Board of Directors regarding a Shareholder Proposal

May 15, 2020 5/15/2020 Takeda Announces Candidates for New Directors

May 15, 2020 5/15/2020 Takeda China announces ADCETRIS® (brentuximab vedotin) is approved for the treatment of adult patients with CD30-positive Lymphomas

May 14, 2020 5/14/2020 Takeda to Present Data at Upcoming Virtual Scientific Congresses, Underscoring Breadth of Oncology Portfolio and Emerging Pipeline

May 14, 2020 5/14/2020 European Commission Approves ADCETRIS® (brentuximab vedotin) for Treatment of Adult Patients with Previously Untreated Systemic Anaplastic Large Cell Lymphoma

May 13, 2020 5/13/2020 Difference between Forecast and Actual Results for the Year Ended March 2020

May 2020